Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: A phase 2 randomized study

Keyphrases

• High Dose 100%
• Estradiol 100%
• Aromatase Inhibitors 100%
• Hormone Receptor-positive 100%
• Serum Estradiol 100%
• Advanced Breast Cancer 100%
• Inhibitor Resistant 100%
• Estradiol Therapy 100%
• Confidence Interval 71%
• Clinical Benefit Rate 42%
• Progression-free Survival 28%
• Stable Disease 28%
• Estrogen Deprivation 28%
• Hormone Receptor-positive Breast Cancer 28%
• Flare Reaction 28%
• Fluorodeoxyglucose F18 28%
• High Risk 14%
• Randomized Trial 14%
• Tumor 14%
• Response Rate 14%
• Adverse Events 14%
• Acquired Resistance 14%
• Tumor Cells 14%
• Daily Dose 14%
• Trial Registration 14%
• Positive Predictive Value 14%
• Positron Emission Tomography-computed Tomography (PET-CT) 14%
• Postmenopausal Women 14%
• Quality of Life 14%
• Serious Adverse Events 14%
• Breast Tumor 14%
• Tumor Response 14%
• Partial Response 14%
• Phase III Clinical Trial 14%
• Treatment Efficacy 14%
• Metabolic 14%
• Adverse Event Rates 14%
• Metastatic Breast Cancer 14%
• Radiological Assessment 14%
• Time to Treatment Failure 14%
• Sensitive Diseases 14%
• Group 11 14%
• Clinical Toxicity 14%
• Resistance to Aromatase Inhibitor 14%
• Breast Cancer Susceptibility 14%
• Deprivation Therapy 14%
• Predictive Properties 14%
• Bone-only Disease 14%
• Co-sensitization 14%
• Laboratory Toxicity 14%
• Toxicity Reaction 14%

Medicine and Dentistry

• Drug Megadose 100%
• Low Drug Dose 100%
• Breast Cancer 100%
• Diethylstilbestrol 100%
• Hormone Receptor 100%
• Aromatase Inhibitor 100%
• Oral 100%
• Diseases 40%
• Adverse Event 30%
• Neoplasm 20%
• Progression Free Survival 20%
• Fluorodeoxyglucose F 18 20%
• Positron Emission Tomography-Computed Tomography 10%
• Clinical Trial 10%
• Tumor Cell 10%
• Postmenopause 10%
• Bone Lesion 10%
• Quality of Life 10%
• Time to Treatment 10%
• Metastatic Breast Cancer 10%
• Survival Time 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Breast Cancer 100%
• Diethylstilbestrol 100%
• Hormone Receptor 100%
• Aromatase Inhibitor 100%
• Diseases 40%
• Neoplasm 30%
• Adverse Event 30%
• Progression Free Survival 20%
• Fluorodeoxyglucose F 18 20%
• Tablet 20%
• Clinical Trial 10%
• Bone Lesion 10%
• Survival Time 10%
• Metastatic Breast Cancer 10%